Owners
MiroBio is a private clinical-stage biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint antibody agonists, to restore immune balance in patients with autoimmune diseases.
History
2022: Gilead bought MiroBio for $405 million
In early August 2022, the American Gilead Sciences signed an agreement to buy the developer of drugs to restore the immune balance MiroBio as part of a deal worth $405 million.
As part of the deal, Gilead Sciences will have access to a research platform and drugs - immune inhibitory receptor agonists developed by MiroBio. Medical drugs are used to restore the immune balance in patients with autoimmune diseases. This was reported on the official website of MiroBio.
MiroBio is a clinically advanced company dedicated to developing therapies to restore immune balance in patients with autoimmune diseases when a person's immune system attacks the body's own tissues. Led by Professor Simon Davis and Professor Richard Cornall, MiroBio withdrew from Oxford University in 2019 and raised $130 million in venture capital funding, including a $97 million tranche from a variety of sponsors, including Oxford Science Enterprises (OSE).
One of these MiroBio products is an antibody MB272 and as of August 2022, the drug is undergoing the first phase of clinical trials, and the first patient in early 2022 received it during trials. This antibody acts on T-, B- and dendritic cells to control the inflammatory immune response in the body.
 | MiroBio has led basic research on agonist antibodies, following a rigorous scientific approach! We believe that MiroBio's unique platform technology can produce best-in-class agonist antibodies that target immune inhibitory receptors, "said Gilead Sciences Research Executive Vice President Flavius Martin. |  |
Gilead Sciences intends to develop other agonists derived from the MiroBio I-ReSToRE platform, including MB151, a PD-1 protein agonist. Gilead Sciences will also work on other projects, company officials said.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |